New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...
ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...
TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced ...
New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, ...
Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...
Managing non-EDC (Electronic Data Capture) data integration in clinical trials is a challenge that holds significant promise. As clinical studies continue to draw on data from wearable devices like ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback